ArticleAmerican journal of hematology2023

Corrigendum to "Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia".

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.